RTX therapy resulted in a substantial decrease in autoantibody titer that was associated with clinical improvement in patients with Chronic inflammatory demyelinating polyneuropathy (CIDP) with primarily IgG4 autoantibodies against NF155, contactin-1, or Caspr1 (113). Here, CNTNAP1 is linked to chronic inflammatory demyelinating polyradiculoneuropathy.